N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study
Jerome Sarris, Georgina Oliver, David A Camfield, Olivia M Dean, Nathan Dowling, Deidre J Smith, Jenifer Murphy, Ranjit Menon, Michael Berk, Scott Blair-West, Chee H Ng
CNS DRUGS | ADIS INT LTD | Published : 2015
BACKGROUND: Obsessive-compulsive disorder (OCD) is a disabling mental illness for which pharmacological and psychosocial interventions are all too often inadequate. Recent preclinical and clinical studies have implicated dysfunction of glutamatergic neurotransmission in the pathophysiology of OCD. The amino acid-based nutraceutical N-acetyl cysteine (NAC) is a safe and readily available agent that has been found to modify the synaptic release of glutamate in subcortical brain regions via modulation of the cysteine-glutamate antiporter. OBJECTIVE: The aim of this study was to assess the efficacy and safety of NAC in treating OCD. METHODS: A 16-week, double-blind, placebo-controlled, randomise..View full abstract
Awarded by National Health and Medical Research Council (NHMRC)
The NAC was kindly donated and supplied by Bioceuticals (R), Alexandria, NSW, Australia. Jerome Sarris is funded by a CR Roper Fellowship, and Michael Berk is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship 1059660.